Sunday, March 12, 2017 9:06:32 PM
3 Ways to profit from this...
1. $17 Billion dollar buyout in 2014 - Mitragyna speciosa (known as kratom) had a brief omnipresence on Wall Street until Fall 2014 when Sigma-Aldrich Corporation, a U.S. based bio-tech company that developed kratom alkaloid solutions was quickly acquired by Merck Group (Merck KGaA), a German big pharm company for $17 billion. Could HADV be next?
2. $125/share for closest competitor GW Pharmaceuticals (NASDAQ: GWPH) , a developer for plant-derived cannabinoid therapeutics. GW Pharmaceuticals has successfully developed [Sativex] the world's first prescription medicine made from the cannabis plant. OTC: HADV is currently under $0.20/share
3. Health Advance (ORC HADV) poised to be the first medical food approved by the FDA on the GRAS list.
RECENT NEWS Link: Recent News Click Here
Stock Research/Quote Current Stock Quote click here
$gwph $hadv
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM